Investment Opportunity
Transforming NHS primary care with AI-powered clinical decision support
Investment Highlights
Proven Clinical Need
NHS primary care under strain. GPs see 30+ patients daily with limited diagnostic support.
Clear Market Opportunity
8,000+ UK GP practices, 60M+ annual consultations. No AI diagnostic tools deployed at scale.
Regulatory Clarity
MHRA pathway defined as Class IIb SaMD. ISO standards established.
Early-Stage Entry
Pre-seed valuation, MVP complete, 18-month path to revenue.
The Problem
NHS Primary Care Crisis
- Record Waiting Times: Patients waiting weeks for GP appointments
- Clinician Burnout: GPs seeing 30-40 patients daily with limited time for each
- Diagnostic Delays: Simple conditions taking months to diagnose due to capacity constraints
- Cost Pressure: NHS budgets stretched while demand increases
- Limited Tools: Most GPs lack AI-powered diagnostic decision support
The Impact: Patients face unnecessary anxiety and treatment delays. GPs struggle with workload. The NHS wastes resources on preventable escalations. HeAIth addresses this at the critical first moment of patient assessment.
Our Solution
AI-powered clinical decision support for NHS primary care, delivering evidence-based diagnostic recommendations at point of care.
Key Differentiators
Doctors Decide, AI Assists
GP Advisory Board guides product decisions.
NHS-First Design
Built for NHS workflows and UK regulatory standards.
Early Diagnostic Focus
Targets initial patient assessment for maximum impact.
Cost-Efficient Architecture
Engineered to maintain low internal costs, enabling competitive NHS pricing and strong margins.
Value Proposition & Cost Analysis
MediScreenAI delivers significant cost savings by optimising the history-taking phase of GP consultations, which represents 5-7 minutes (66%) of consultation time.
Per Consultation Economics
Traditional Approach
6 minutes GP questioning
AI-Assisted Approach
1.5 minutes GP review + £1.50 AI cost
Cost Savings per Consultation
70% reduction in history-taking costs | 4.5 minutes saved (75% time reduction)
Return on Investment
NHS-Wide Impact Potential
With 1.3 million daily GP consultations in the UK:
Clinical Efficiency Gains
- ✓ 4.5 minutes freed up per consultation for physical examination and patient explanation
- ✓ More thorough history gathering through structured AI questionnaires
- ✓ Reduced diagnostic errors through comprehensive symptom capture (80% of diagnoses made on history alone)
- ✓ Better preparation allows GPs to focus on clinical reasoning rather than information gathering
View Complete Analysis: Detailed cost breakdown, methodology, and NHS research citations
Download Full Cost Analysis (PDF)Based on NHS England data, Personal Social Services Research Unit (PSSRU) study, and peer-reviewed medical research
Market Opportunity
Total Addressable Market
Expansion Pathways
Secondary care, private sector, international markets (EU, Commonwealth), telemedicine platforms.
Regulatory Pathway & Timeline
Pursuing MHRA authorisation as Class IIb SaMD via proven regulatory pathway.
Q4 2025 - Q1 2026
Advisory Board Formation
Recruit 3-5 GP advisors, define clinical scope.
Q2-Q3 2026
Clinical Validation & ISO Certification
Multi-site studies, ISO 13485/14971/IEC 62304.
Q4 2026 - Q1 2027
MHRA Submission
Regulatory submission and review.
Q2-Q3 2027
Pilot Deployment
Early NHS partners, real-world validation.
Q4 2027
UK Market Launch
Scale to 50-100 practices Year 1.
2028+
Refinement & International Expansion
Cost optimisation, EU/US market preparation.
Seed Funding Allocation
£500k-700k seed round: ISO certification and MHRA submission, clinical validation, NHS EHR integration, team expansion (Medical Director, Regulatory Affairs Manager, engineers), NHS partnerships and pilot deployment.
Use of Funds
Seed funding will be deployed strategically across regulatory approval, team expansion, and market preparation.
MHRA pathway, ISO certification, clinical validation studies, quality management systems
Engineering team expansion, NHS EHR integration, platform refinement, security infrastructure
Clinical advisor compensation, medical director hire, clinical validation team
Company formation, legal compliance, insurance, operational infrastructure
Team & Advisors
Founder
Maximus Smith - BSc Mathematics, Software Engineer
Founded HeAIth after successfully using AI to diagnose own medical condition, saving £200+ and months of waiting. Built working MVP in one week. Deep understanding of both technical AI implementation and patient/clinician needs.
Clinical Advisory Board (Forming)
Recruiting 3-5 practicing GPs and frontline NHS clinicians to guide all product and clinical decisions. Advisory board members receive equity compensation and play crucial role in ensuring clinical validity and NHS workflow integration.
Planned Hires (Post-Funding)
- Medical Director: Qualified clinician to lead clinical strategy and validation
- Regulatory Affairs Manager: MHRA submission and compliance expertise
- Senior Software Engineers (2): NHS integration and platform scaling
- Clinical Validation Specialist: Evidence generation and trial management
Investment Terms
Round Type
Seed Round (SAFE or Equity)
Target Raise
£500,000 - £700,000
Stage
Pre-seed / Seed
Timeline
Q1-Q2 2026
Ideal Investor Profile
- Healthcare-focused VCs or angel investors
- Investors with NHS or UK healthcare experience
- Impact investors focused on improving healthcare access
- MedTech or HealthTech sector specialists
- Strategic investors with NHS connections or regulatory expertise
Note: Detailed terms, valuation, and investment documentation available to qualified investors upon request. All investments subject to UK financial regulations and investor accreditation requirements.
Interested in Learning More?
We are actively engaging with investors who share our vision of improving NHS primary care through responsible AI implementation.
Contact Maximus Smith, Founder for:
- Detailed investment deck and financial projections
- Product demonstration (non-clinical)
- Due diligence materials
- Regulatory pathway documentation
- Market analysis and competitive landscape
Email: maximus.smith@heaith.co.uk
Subject: "Investment Inquiry"